The present invention relates to a new class of biomarkers in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining a disease state or a health condition, wherein such condition is correlated with one or more ErbB cell surface membrane receptors measured directly in a patient sample, particularly a fixed tissue sample. associated with the number of aggregates. In another aspect, the invention includes a method of determining the status of cancer in a sample from an individual, wherein a measure of the amount of one or more ErbB cell surface receptor dimers in the cells of the sample is correlated with the status, comprising Presence or absence of a precancerous state, presence or absence of a cancerous state, cancer prognosis, or responsiveness to therapy. Preferably, the methods of the invention are carried out by employing panels of binding compounds with releasable molecular tags specific for various components of one or more types of receptor dimers. After binding, the molecular tags are released and isolated from the assay mixture for analysis.